2021年8月2日月曜日
早速・・・
FDA authorizes Regeneron's COVID-19 antibody cocktail treatment to be used as a drug to PREVENT the disease in high-risk patients
- The FDA approved Regeneron's antibody cocktail REGEN-COV to also be used as a preventive treatment against COVID-19 on Friday
- It can be used for those at high risk of exposure in settings such as nursing homes who who are high risk because they have weakened immune systems
- Trial data released in April showed the drug reduced the risk of symptomatic infections by 72% in the first week, and 93% after that
- In its statement expanding the authorization, the FDA said REGEN-COV is not a replacement for vaccination
The U.S. Food and Drug Administration (FDA) authorized Regeneron's COVID-19 antibody cocktail to be used as a preventive treatment on Friday.
The combo therapy, REGEN-COV, was approved in November 2020 for emergency use to treat people with mild-to-moderate COVID-19 cases in the U.S.
But the expanded authorization now enables the drug to also be used a prophylactic for patients who are at high risk of exposure in settings such as nursing homes or prisons.
It could also help reduce the risk of infection for those with weakened immune systems including those with HIV, organ transplant patients and people suffering from autoimmune diseases
The antibody cocktail, REGEN-COV, is a combination of two drugs: casirivimab and imdevimab.
Both are monoclonal antibodies that target the the spike protein, which the virus uses to enter and infect cells.
These cocktails deliver virus-fighting antibodies into the body unlike traditional vaccines in which the receiver's immune system is activated to develop its own antibodies.
According to trial data released in April, the drug reduced the risk of symptomatic infections by 72 percent in the first week, and 93 percent after that,
What's more, it lowered the risk of symptomatic infections by 81 percent when used by those who were exposed to household individuals that had the virus.
Additionally, researchers found the cocktail reduced the risk of infection by 76 percent among patients considered high risk of becoming severely ill.
When used by among those who did develop symptoms, the treatment group cleared the virus faster than those in the placebo group.
Regeneron said the expanded authorization will help address the needs of immunocompromised people, including those taking immunosuppressive medicines, whose bodies may not mount an adequate response to COVID-19 vaccination.
Nobody treated with REGEN-COV group developed serious side effects such as as life-threatening allergic reaction.
Dr Myron Cohen, a professor of epidemiology at the University of North Carolina at Chapel Hill and one of the researchers studying Regeneron's cocktail as a prevention method said the drug is most protective while the virus is the nose and throat.
'It's a race between your ability to make an antibody to protect your lungs and the rest of your body and the virus,' he told NBC News.
'And if you're likely to lose the race, you're the person for whom these antibody drugs are appropriate.'
In its statement announcing the authorization, the FDA said the expanded approval is not a substitute for vaccination.
The federal health agency said any American should get immunized against the disease. https://www.dailymail.co.uk/health/article-9845333/FDA-okays-Regeneron-COVID-19-antibody-preventive-high-risk-settings.html
実質的にトランプ大統領大勝利ですな。（爆ｗｗｗｗｗｗｗｗｗｗｗｗ
政治的配慮かFDAはコレはワクチンの代替え品ではないと言ってますが、これで死亡する確率が激減するなら実質的にはもうｍRNAワクチンは無意味って事なわけです。（爆ｗｗｗｗｗｗｗｗｗ
で、ワクチンマフィアがデマ流しまくって必死なわけですな・・・（爆ｗｗｗｗｗｗｗｗｗｗｗｗ
やっぱＡｕｇｕｓｔでしたね・・・（爆ｗｗｗｗｗｗｗｗｗｗ
1 件のコメント:
コロナ典型症状
出た事はないけど
本来風邪引き易いし
過去3回風邪気味はあった(苦
もし典型症状が出たら
ロナプリーブ点滴静注セット
宜しくお願いしますw
コメントを投稿